Expertise in
31
conditions

Dr. Sudipto Mukherjee

Hematology | Oncology
9500 Euclid Avenue, 
Cleveland, OH 
 (2015.4 mi)
On Staff At
Offers Telehealth
Expertise in
31
conditions
9500 Euclid Avenue, 
Cleveland, OH 
 (2015.4 mi)
OverviewInsuranceLocationsClinical Research

Overview

Sudipto Mukherjee is a Hematologist and an Oncologist in Cleveland, Ohio. Dr. Mukherjee is highly rated in 31 conditions, according to our data. His top areas of expertise are Multicentric Castleman Disease (MCD), Castleman Disease, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Thyroidectomy.

His clinical research consists of co-authoring 109 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in MI
Hospital Affiliations
Cleveland Clinic
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Oscar
  •  Humana

Locations

Cleveland Clinic Main Campus
9500 Euclid Avenue, Cleveland, OH 44195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Exploratory Analysis of the Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease
Exploratory Analysis of the Molecular Basis of Langerhans and Non-Langerhans Cell Histiocytic Neoplasms and Castleman Disease
Enrollment Status: Suspended
Publish Date: February 04, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Active_not_recruiting
Publish Date: January 08, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
Lower Doses of CPX-351 as a Novel Approach for the Treatment of Older Patients With Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
Lower Doses of CPX-351 as a Novel Approach for the Treatment of Older Patients With Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes
Enrollment Status: Active_not_recruiting
Publish Date: January 03, 2025
Intervention Type: Drug
Study Drugs: Daunorubicin, Cytarabine
Study Phase: Phase 2
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2024
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
A Phase 1 Study of Safety, Pharmacokinetics and Preliminary Activity of TAS1553 in Subjects With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Enrollment Status: Terminated
Publish Date: August 02, 2024
Intervention Type: Drug
Study Drug: TAS1553
Study Phase: Phase 1
A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With Acute Myeloid Leukemia Undergoing Remission Induction Therapy
A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With Acute Myeloid Leukemia Undergoing Remission Induction Therapy
Enrollment Status: Unknown
Publish Date: December 01, 2021
Intervention Type: Drug
Study Drug: Eltrombopag
Study Phase: Phase 2
View 5 Less Clinical Trials

109 Total Publications

Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.
Journal: JAMA oncology
Published: November 21, 2024
Similar Doctors
Expertise in
30
conditions
Dr. Jaroslaw P. Maciejewski
Hematology | Oncology
Expertise in
30
conditions
Dr. Jaroslaw P. Maciejewski
Hematology | Oncology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jaroslaw Maciejewski is a Hematologist and an Oncologist in Cleveland, Ohio. Dr. Maciejewski is highly rated in 30 conditions, according to our data. His top areas of expertise are Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH), Myelodysplastic Syndrome (MDS), Bone Marrow Transplant, and Splenectomy.

Expertise in
25
conditions
Dr. Anjali S. Advani
Hematology | Oncology
Expertise in
25
conditions
Dr. Anjali S. Advani
Hematology | Oncology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
Languages Spoken:
English
See accepted insurances

Anjali Advani is a Hematologist and an Oncologist in Cleveland, Ohio. Dr. Advani is highly rated in 25 conditions, according to our data. Her top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
31
conditions
Dr. Deepa Jagadeesh
Hematology | Oncology
Expertise in
31
conditions
Dr. Deepa Jagadeesh
Hematology | Oncology

Cleveland Clinic Main Campus

9500 Euclid Avenue, 
Cleveland, OH 
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Deepa Jagadeesh is a Hematologist and an Oncologist in Cleveland, Ohio. Dr. Jagadeesh is highly rated in 31 conditions, according to our data. Her top areas of expertise are T-Cell Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile